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Ferritin nanocages loaded with gold ions induce
oxidative stress and apoptosis in MCF-7 human
breast cancer cells†
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Francesca Pane,a Angela Amoresano,a Maria Agostina Cinellu b and
Antonello Merlino *a
Two anticancer gold(III) compounds, Au2phen and Auoxo4, were encapsulated within a ferritin nanocage.
The gold-compound loaded proteins were characterized by UV-Vis spectroscopy, inductively coupled
plasma mass spectrometry and circular dichroism. X-ray crystallography shows that the compounds
degrade upon encapsulation and gold(I) ions bind Ft within the cage, close to the side chains of Cys126.
The gold-encapsulated nanocarriers are cytotoxic to human cancer cells. Au(I)-loaded Ft, obtained upon
the encapsulation of Au2phen within the cage, induces oxidative stress activation, which ﬁnally leads to
apoptosis in MCF-7 cells.
Introduction
There is currently great interest in the development of new bio-
materials that can be used to selectively deliver drugs to their
final targets. Nature oﬀers a variety of protein scaﬀolds that
self-assemble to form cages within the nanometer scale and
can be used to trap drugs in their interior cavity. Among these
systems, a special position is occupied by the ferritin super-
family.1 The mammalian iron-storage protein ferritin (Ft) is a
heteropolymer consisting of two genetically distinct subunits,
called the H-chain (∼21 kDa) and L-chain (∼19 kDa). Ft is a
four-helix bundle protein which forms a cage of 24 monomers
(Ft nanocage), which is characterized by an octahedral 432
symmetry, with internal and external diameters of ∼80 and
∼120 Å, respectively.2 Ft is fundamental for life: its role is to
protect cells from oxidative damage caused by the harmful
products of the Fenton reaction and to store iron.
A Ft cage is an attractive carrier for targeted drug deliv-
ery,1,3,4 since it is not expensive, available in a large amount,
easy to purify, biocompatible, stable and monodisperses
in the bloodstream. Ft is also characterized by a small size
compared to other potential drug carriers; its structure allows
chemical modifications, including the conjugation of diﬀerent
chemical groups.5 Most importantly, it is recognized and inter-
nalized by specific receptors which are over-expressed in a
variety of malignant cells: the transferrin receptor 1 (TfR1) and
Scara5.6–8
It was earlier shown that cisplatin9 and the second gene-
ration Pt antitumor drug carboplatin10 can be encapsulated in
the cavity of apoferritin (AFt); the resulting drug-loaded pro-
teins have well documented cytotoxic eﬀects on tumor cells
(pheochromocytoma, gastric, breast, cervix and melanoma
cells),11–14 demonstrating the eﬃciency of Ft as a carrier of
these drugs to malignant cells.
Gold-based compounds have emerged as a promising class
of anticancer agents as an alternative to Pt-based drugs.15–18
However, the clinical use of these potential drugs has been
until now hampered by a series of factors, including their low
solubility and stability in aqueous media.15–18 Greater solubi-
lity and stability could be obtained by encapsulation of gold-
based drugs within a protein nanocage. Ft-gold drug adducts
could also have the advantage of enhanced selectivity for
tumor cells.19
Recently, we have successfully encapsulated the gold-based
drug [Au2(bipy
Me)2(μ-O)2][PF6]2 (bipyMe = 6-methyl-2,2′-bipyri-
dine), Auoxo3, with a AFt nanocage.19 The drug-loaded protein
is cytotoxic towards diﬀerent malignant cells (HeLa, MCF-7
and HepG2) and shows a lower toxicity for non-malignant cells
(H9c2, HRCE and HaCaT).19 The incorporation of Auoxo3
inside the cage leads to the formation of gold(I) ions that bind
AFt close to the side chains of Cys126, Cys48, His49, His132,
and His147. The UV-Vis spectrum of Auoxo3-encapsulated AFt
also suggests the formation of a small amount of gold nano-
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particles (Fig. S3 in the ESI of ref. 19), which absorb at
548 nm, in agreement with what has recently been observed
for gold nanoparticles formed upon the reduction of a AuCl4
−
encapsulated Ft variant with NaBH4.
20
Here, we have encapsulated two other gold-based drugs of
medicinal interest, namely [Au2(bipy
nP)2(μ-O)2][PF6]2 (bipynP =
6-neo-pentyl-2,2′-bipyridine), Auoxo4, and [Au2(Me2phen)2
(μ-O)2][PF6]2 (Me2phen = 2,9-dimethyl-1,10-phenanthroline),
Au2phen, (Fig. 1) in an AFt nanocage. Auoxo4 and Au2phen
are both more cytotoxic than Auoxo3,17,21–24 and thus we
expect an increased cytotoxicity of these Ft adducts when
compared to the previously characterized Auoxo3-encapsu-
lated AFt. X-ray structures of Au2phen- and Auoxo4-encapsu-
lated AFts were solved and the cytotoxicity of the two adducts
was assessed by MTT assay on human MCF-7 and HeLa
cancer cell lines and on non-cancer cells H9c2 and HaCaT.
The data indicate that gold nanoparticles are not formed
inside Au2phen- and Auoxo4-encapsulated AFt cages. New
adducts are much more cytotoxic than the Auoxo3-encapsu-
lated AFt. The activation of oxidative stress and of apoptosis
in MCF-7 cells treated with Au2phen-loaded AFt is also
reported.
Results
Preparation and characterization of gold compound-
encapsulated AFt
The potential antitumor drug-loaded nanostructure was pre-
pared using the procedure previously described by Huang
et al.14 and already used to encapsulate cisplatin,9 carbopla-
tin10 and the gold-based drug Auoxo3,19 which belongs to the
Auoxos, i.e. a series of dinuclear gold(III) oxo-bridged com-
plexes supported by substituted 2,2′-bipyridine (e.g. 6-methyl-
2,2′-bipyridine and 6-neo-pentyl-2,2′-bipyridine in Auoxo3 and
Auoxo4, respectively) or 1,10-phenanthroline (e.g. 2,9-dimethyl-
1,10-phenanthroline in Au2phen) ligands.
20–22,23,24
The Ft cage can be disassembled at both acidic and basic
pH values. We have preferred the protocol using the basic pH,
so that we can directly compare our new data with those pre-
viously obtained with Auoxo3.19
Thus, in order to disassemble the Ft cage into subunits,
horse spleen ferritin was incubated for 20 minutes at pH 13
after adding NaOH up to a final concentration of 0.1 M. This
solution was then mixed with powdered Au2phen and Auoxo4
and the two samples were incubated for 30 minutes at room
temperature under stirring. Then, pH was decreased to 7.4
using 1.0 M sodium phosphate. The two gold-encapsulated
samples were then dialysed through ultracentrifugation on
centricon filters (10 kDa cutoﬀ ) to remove the excess drugs. To
confirm the encapsulation of gold compounds within the Ft
shell and verify that upon encapsulation the protein re-assem-
bles readopting its native conformation, UV-Vis absorption
spectroscopy (Fig. 2A), circular dichroism (Fig. 2B) and induc-
tively coupled plasma mass spectrometry (ICP-MS) data were
collected.
UV-Vis spectra of Au2phen and Auoxo4-encapsulated AFt
were compared with those of AFt, used as a control, and of
Auoxo3-encapsulated AFt. Contrary to what was found for
Fig. 2 UV-Vis absorption spectra (A) and far-UV CD spectra (B) of gold-
encapsulated Fts compared to the drug-free protein (control). UV-Vis
spectra were acquired using a protein concentration of 0.25 mg mL−1 in
10 mM sodium phosphate at pH 7.4. Far-UV CD spectra were acquired
using a protein concentration of 0.1 mg mL−1 in 10 mM sodium phos-
phate at pH 7.4. The superposition of the curves in the region between
250 nm and 280 nm conﬁrms that the drugs are successfully encapsu-
lated in the nanocage.
Fig. 1 Structure of selected gold(III) compounds of interest for their
antitumor action.
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Auoxo3-encapsulated AFt (see Fig. 2A),19 there is no absorption
at 548 nm in the UV-Vis spectra of the new encapsulated AFts,
indicating that gold nanoparticles are not formed when these
two compounds are within AFt. This indication was further
supported by the inspection of the colour of the Auoxo4- and
Au2phen-encapsulated AFt solutions, which appear light
yellow and remain in this colour for weeks, at variance with
that of Auoxo3-encapsulated AFt which turns violet with time
(Fig. S1†). The ICP-MS data indicate that the Ft nanocage can
encapsulate 0.6 to 24 gold atoms per subunit, depending on
the preparation. The data reported in this paper were collected
for the samples of Auoxo4- and Au2phen-encapsulated AFt
solutions containing 16 and 18 atoms of gold per Ft chain, i.e.
384 and 432 Au atoms per cage in the case of Auoxo4 and
Au2phen, respectively. Interestingly aged-samples of Au2phen-
encapsulated AFt (10 months) retain the same amount of gold
inside the cage when compared to freshly prepared samples.
Far-UV circular dichroism measurements reveal that the
initial Ft secondary structure content was restored upon the
encapsulation procedure (Fig. 2B).
X-ray structure analysis of Auoxo4-encapsulated AFt and
Au2phen-encapsulated AFt
As indicated by Tosi and co-workers,25 the eﬀective clinical
translation of drug-encapsulated Ft nanocages is probably
limited also by the poor knowledge of the consequence of the
protocols used to encapsulate the drugs on the overall architec-
ture and structure of the nanocage. Circular dichroism is the
technique that was most frequently used to evaluate the eﬀects
of the encapsulation protocols on the Ft structure. Although
this technique provides reliable information on the secondary
structure content of Ft, it does not show a real representation
of the integrity of the cage after the disassembly/assembly
process. X-ray crystallography is certainly the best choice to
characterize the structure of the adducts. The X-ray structures
of Au2phen-encapsulated AFt and Auoxo4-encapsulated AFt
were solved at 1.82 and 2.60 Å resolution, respectively (Fig. 3A)
and compared with those of a ligand-free protein and of the
adduct formed upon the encapsulation of Auoxo3. The two
structures were solved using the structure of the drug-free
protein as a starting model and refined to an Rfactor of 0.161
and 0.184 and an Rfree of 0.187 and 0.236, respectively.
Positions of gold atoms in the structure were unambigu-
ously identified by inspection of anomalous and 2Fo-Fc e.d.
maps.
The structures are very similar to each other: they superim-
pose with a root mean square deviation between carbon alpha
atoms of 0.38 Å. The structures of both Au2phen-encapsulated
AFt and Auoxo4-encapsulated AFt present two gold atoms
bound to the side chains of Cys126 (Fig. 3B), whereas that of
Auoxo3-encapsulated AFt shows gold atoms bound to the side
chains of Cys126, Cys48, His49, His132, and His147.19
The geometry around the metal centres is linear, indicating
that gold is probably in the oxidation state +1. The extensive
degradation of the compounds and the reduction of the gold
atom from +3 to +1 are not surprising since they were already
observed in many other adducts of gold(III) based drugs with
proteins, including members of the Auoxo series.26–29
We have searched for the origin of the diﬀerent behaviour
of Auoxo3, when compared to Auoxo4 and Au2phen, in the bio-
physical properties of the three compounds. Auoxo3 and
Auoxo4 are structurally very similar and have similar redox
potentials (Auoxo3: Ep = −0.41 V vs. SCE in DMSO, corres-
ponding to Ep = −0.39 V vs. NHE in aqueous solutions;
Auoxo4: Ep = −0.40 V vs. SCE in DMSO, corresponding to Ep =
−0.38 V vs. NHE in aqueous solutions). However, these two
structurally related compounds show a diﬀerent rate of hydro-
lysis reaction, which probably precedes the reduction process
(half-life time at 70 °C (t1/2) = about 1 h and 9 h for Auoxo3
and Auoxo4, respectively). This diﬀerence, which we believe
Fig. 3 Overall structure of the Au2phen-encapsulated AFt subunit with
the Bijvoet diﬀerence Fourier map calculated with the anomalous data
and reported at 4σ (A). An enlargement of the gold binding site region
with the anomalous map is reported in Fig. S2.† In panel B, 2Fo-Fc elec-
tron density maps at 0.8σ (cyan) and 4σ (blue) of gold ions coordinated
to Cys126 are reported. The gold ions were reﬁned with partial occu-
pancy (0.50 and 0.30); the average B-factors for gold ions are in the
range 16.7–48.1 Å2. Similar results were obtained for Auoxo4-encapsu-
lated AFt (Fig. S3 and S4†). The structures were deposited in the Protein
Data Bank under accession codes 6ENW and 6ENV.
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could be the basis of the diﬀerent behaviour of the two com-
pounds, should be attributed to the presence of a large, hydro-
phobic, neopentyl group in the structure of Auoxo4, which pro-
tects the Au atom from the nucleophilic attack by water mole-
cules (or by OH− at alkaline pH) more eﬀectively than the
small methyl group.
Au2phen behaves diﬀerently when compared to Auoxo3
probably because of its highly negative redox potential (Epc1 =
−0.946 V and Epc2 = −1.329 V vs. Fc+/Fc at a scan rate of
0.1 V s−1),23 which indicates high redox stability. Thus, both
Au2phen and Auoxo4 have a lower tendency for reduction than
Auoxo3 and this could explain both the lower number of
gold(I) binding sites observed in the structure of the encapsu-
lated AFts here reported when compared to Auoxo3-encapsu-
lated AFt and the higher tendency of Auoxo3 to form gold
nanoparticles inside the Ft cage when compared to Au2phen
and Auoxo4.
Cytotoxicity
To assess the cytotoxic eﬀect of Auoxo4- and Au2phen-encapsu-
lated AFts to inhibit cell growth, diﬀerent cell lines were ana-
lysed. In particular, two cancer cell lines, human epithelial
breast (MCF-7) and cervix carcinoma (HeLa) cells, and two
normal cell lines, rat cardiomyoblasts (H9c2) and human kera-
tinocytes (HaCaT) were used. The cells were incubated for 48 h
with increasing concentrations of Auoxo4- and Au2phen-encap-
sulated AFts, as well as with increasing concentrations of the
free gold-based drugs. Then the ability of functional mitochon-
dria to catalyse the reduction of MTT to form formazan salt by
mitochondrial dehydrogenases was evaluated.30 Drug-free Ft
has already been used as a control in a previous paper and it
did not show significant toxicity to any of the analysed cell
lines.19
The results obtained after 48 h of incubation of cells
with the new adducts are reported in Fig. 4 and show typical
dose–response curves. The corresponding IC50 values, sum-
marized in Table 1, indicate that, after 48 h incubation, encap-
sulated nanocages are more toxic towards cancer cell lines
than towards normal cells. It is particularly interesting to
underline that the presence of the cage significantly reduces
the toxicity of the free gold drugs towards the non-cancer cell
lines, enhancing the selectivity of the gold compounds
towards tumour cells. Moreover, the new encapsulated AFts are
more active than the Auoxo3-encapsulated AFt, for which IC50
values were determined after 72 h.19
In this respect, it is noteworthy that there are diﬀerences in
the cytotoxicity profiles of the two gold-encapsulated AFts that
are probably due to the diﬀerent amounts of gold that is
Fig. 4 Eﬀects of Au2phen-encapsulated AFt (A), Au2phen (B), Auoxo4-
encapsulated AFt (C) and Auoxo4 (D) on human cancer (HeLa and
MCF-7) and normal cells (HaCaT and H9c2). The cells were treated with
increasing amounts of the cage and of the free drug for 48 hours. Cell
viability was assessed by the MTT assay and expressed as described in
the Materials and methods section. All values are given as means ± SD.
Table 1 IC50 values (µM) obtained for Au2phen, Auoxo4 and Au2phen-
and Auoxo4-encapsulated AFts in HeLa, MCF-7, H9c2 and HaCaT cell
lines. Concentrations refer to the amount of gold
IC50, µM,
48 h
Au2phen-
encapsulated
AFt Au2phen
Auoxo4-
encapsulated
AFt Auoxo4
HeLa 32 ± 4 6.5 ± 1.0 23 ± 9 13.74 ± 0.96
MCF-7 6 ± 1 10.6 ± 2.5 30 ± 1 34.8 ± 4.3
H9c2 40 ± 1 1.28 ± 0.06 68 ± 6 14.6 ± 1.4
HaCaT 36 ± 9 14.3 ± 1.7 73 ± 6 12.4 ± 1.6
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encapsulated within the Ft and thus internalized by the cells.
Moreover, it should also be recalled that since the structures of
Auoxo4- and Au2phen-encapsulated AFts are similar, the diﬀer-
ences should be due to the gold compounds that are within
the cage, i.e. in the bulk. Interestingly, cytotoxicity experiments
carried out on an aged-sample of Au2phen-encapsulated AFt
(10 months) lead to results that are very similar to those
obtained by using freshly prepared samples, thus suggesting a
high stability of the protein adduct.
Uptake data
To obtain a deeper insight into the amount of gold that is
internalized by the cells, ICP-MS data on the uptake of
Au2phen and Au2phen-encapsulated AFt, tested at the concen-
tration needed to reach IC50 values, were collected. We found
that the amount of gold uptake by MCF-7 cells is variable with
Au2phen, with values ranging from 2.2 µg up to 12.8 µg of gold
per 1.5 × 106 cells, whereas it is constant in the case of
Au2phen-encapsulated AFt, with values close to 0.06 µg of gold
per 1.5 × 106 cells. These data indicate that the use of Ft
strongly reduces the gold uptake and that the amount of Au
internalized by the cells needed to kill 50% of them when they
are treated with the free drug is 30–100 times higher than that
needed when the cells are treated with Au2phen-encapsulated
AFt. Moreover, it is found that the Au2phen-encapsulated AFt
is slightly more cytotoxic than the free gold complex. These
findings indicate that the mode of action of the drug encapsu-
lated within the cage is significantly diﬀerent and more
eﬃcient when compared to that of the free drug, which enters
the cells via passive diﬀusion. Further studies are needed to
deeply analyse the reason for the greater cytotoxicity of
Au2phen-encapsulated AFt when compared to the free gold
complex and the exact mechanism of action of these potential
gold-based drugs.
Au2phen-encapsulated AFt induces oxidative stress and apop-
tosis in MCF-7 human breast cancer cells
As it has been recently reported that ferrocenylated
N-heterocyclic carbene supported gold(I) compounds are able
to induce oxidative stress and subsequent cell death in cancer
lung cells,31 we analysed if Au2phen-encapsulated AFt, which
is endowed with the highest cytotoxic activity toward malig-
nant cells, was able to alter the redox state of MCF-7 (the most
sensitive cells to Au2phen-encapsulated AFt). As shown in
Fig. 5A, we found an increase in ROS levels after 6 h of incu-
bation with Au2phen-encapsulated AFt and the drug alone,
whereas no eﬀect was observed for drug-free AFt. It is known
that mitochondria are sensitive to changes in the cellular
redox status and ROS activation is known to induce depolariz-
ation of the mitochondrial membrane.32 For this reason, we
measured the mitochondrial potential of MCF-7 cells after
Au2phen-encapsulated AFt and Au2phen treatment by TMRE
(Mitochondrial Membrane Potential) assay33 overtime
(Fig. 5B).
We observed that after 6 h of incubation, the fluorescence
intensity significantly decreases in the cells treated with
Fig. 5 Activation of the oxidative stress pathway in MCF-7 cells after
treatment with Au2phen-encapsulated AFt and Au2phen. MCF-7 were
incubated in the presence of 7 µg mL−1 of Au2phen-encapsulated AFt
and 12 µg mL−1 of Au2phen for diﬀerent lengths of time (2 to 24 h) and
markers of the oxidative stress were evaluated. Time-dependent
changes in ROS levels were detected with a DCFDA probe and
expressed as the ﬂuorescence intensity percentage over control (%)
(panel A). Time-dependent changes in the mitochondrial membrane
potential (Δψm) were determined using TMRE staining and expressed as
the TMRE ﬂuorescence intensity over control (%) (panel B). Intracellular
GSH levels were determined by DTNB assay after 6 h of incubation.
Values are expressed as a fold increase with respect to control cells
(panel C). Western blotting of the phosphorylation level of p38 (upper
panel) after 24 h of incubation, with the relative densitometric analysis
(panel D). GAPDH (lower panel) was used as an internal standard. The
data shown are the means ± S.D. of three independent experiments.
* indicates p < 0.001, ** indicates p < 0.0001, *** indicates p < 0.00001.
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Au2phen and Au2phen-encapsulated AFt, when compared to
untreated cells, thus suggesting that the treatment results in
the dissipation of the mitochondrial membrane potential
(Δψm). However, the lowest permeability threshold was found
after 9 h of treatment and remained constant up to 24 h of
incubation. This implies mitochondrial damage during treat-
ment with the Au2phen-encapsulated AFt and drug alone.
Furthermore, a decrease in intracellular GSH levels after 6 h
of treatment (Fig. 5C) and the increase in the phosphorylation
level of p38, a protein involved in inflammation, cell cycle,
development, diﬀerentiation and death, senescence and
tumorgenesis34 confirmed the activation of the oxidative stress
pathway (Fig. 5D).
We finally analysed if apoptosis occurred in our experi-
mental system, since it is known that cells are driven to apop-
tosis when ROS levels become too high.31,35 The cells were
incubated for 48 h in the presence of Au2phen-encapsulated
AFt and Au2phen and the activation of Caspases 8 and 3 was
analysed. As shown in Fig. 6, both Caspases were activated
after 48 h incubation.
We hypothesize that apoptosis is triggered by the release
of the drug inside the cell, in agreement with the data
obtained by Zhang et al. who have demonstrated that Ft can be
internalized through TfR1 and can dissociate and release its
cargo upon acidification of the endosomal compartment.36
Materials and methods
Sample preparation
Horse spleen ferritin was purchased from Sigma (code F4503,
about 90% L chain) and used without further purification.
A stock solution of Ft was stored at 4 °C in 0.15 mM sodium
chloride. Gold based drugs Auoxo4 and Au2phen were syn-
thesized as previously described.20–22,23 Au2phen-encapsulated
AFt and Auoxo4-encapsulated AFt were prepared using the
same procedure, i.e. following the protocol we have already used
to encapsulate cisplatin,9 carboplatin10 and gold-based drug
Auoxo3.19 The AFt protein nanocage was first dissociated into
individual subunits at pH 13, using NaOH (final concentration
0.1 M), in the presence of the drug (protein to gold compound
molar ratio 1 : 50), and then reassembled at pH 7.4 using 1.0
M sodium phosphate buﬀer. During the reassembly process,
gold compounds were trapped within the inner cavity of the
cage. The reaction solution was slowly stirred during all steps.
The final solution was ultracentrifuged at 5000 rpm to remove
the abundant precipitate and the supernatant recovered was
then dialyzed using centricon filters (10 kDa cutoﬀ ) against
10 mM sodium phosphate buﬀer, pH 7.4 to remove the excess
of the drug that is unbound.
Analytical and biophysical characterization of the samples
ICP-MS data were collected to confirm the encapsulation of
gold compounds inside the cages, to quantitatively evaluate
the eﬃciency of the gold compound encapsulation and esti-
mate the amount of gold inside the cells. Gold standard solu-
tions were prepared in 5% HNO3 at 4 diﬀerent concentrations
(1, 10, 50, and 100 μg L−1). The Au concentration was
measured. All the analyses were performed in triplicate.
To determine the amount of gold inside the cells, treated
and untreated cells were extensively washed with PBS and ali-
quots of the medium of treated and untreated cells and their
cell pellets were incubated with 200 μl of 65% HNO3 (Sigma
Aldrich) and 600 μl of 35% HCl (Sigma Aldrich) overnight at
90 °C. The solution was then transferred into polystyrene
liners, diluted at 1 : 10 v/v with 5% HNO3 and finally analysed
with an Agilent 7700 ICP-MS from Agilent Technologies,
equipped with a frequency-matching RF generator and a 3rd
generation Octopole Reaction System (ORS3), operating with
helium gas in ORF. The following parameters were used: radio-
frequency power 1550 W, plasma gas flow 14 L min−1; carrier
gas flow 0.99 L min−1; He gas flow 4.3 mL min−1. 103Rh was
used as an internal standard (final concentration: 50 μg L−1).
The error in the determination of the amount of gold within
the cells is within 10%.
The data indicate that Auoxo4-encapsulated AFt and
Au2phen-encapsulated AFt contained a variable Ft subunit to
Au ratio, depending on the preparation, and an undetectable
amount of iron, confirming that the protein is in the Apo form
(AFt) in the final adduct.
The gold compound-encapsulated AFts were also character-
ized by obtaining UV-Vis absorption and circular dichroism
spectra.
UV-Vis absorption spectra were recorded on a Jasco V650
UV-visible spectrophotometer in 10 mM sodium phosphate at
pH 7.4 by using the protein at a concentration of 0.25
mg mL−1. Experimental conditions: 240–700 nm wavelength
range, 200 nm min−1 scanning speed and 1 nm data pitch.
CD spectra were recorded on a Jasco V815 spectropolari-
meter in the 190–250 nm range using a protein concentration
of 0.1 mg mL−1 in 10 mM sodium phosphate at pH 7.4.
Experimental conditions: 2 nm bandwidth, 50 nm min−1 scan-
ning speed, 1 nm data pitch and 4 s response time.
Fig. 6 Apoptosis activation in MCF-7 incubated with Au2phen-encap-
sulated AFt and Au2phen. The cells were incubated for 48 h in the pres-
ence of 7 µg mL−1 of Au2phen-encapsulated AFt and 12 µg mL
−1 of
Au2phen and then cell extracts were prepared and subjected to western
blotting analysis. Western blotting was performed using anti Caspase-3,
which recognizes the activated form of the protein and anti Caspase-8,
which recognizes pro-Caspase-8 and the activated forms (p43/41 and
p18). GAPDH was used as the loading control.
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Crystallization and X-ray diﬀraction data collection
Auoxo4- and Au2phen-encapsulated AFts were crystallized by
the hanging-drop vapor diﬀusion method at 298 K: 1 µL drops
of 5 to 10 mg mL−1 protein adduct were mixed with equal
volumes of 0.6–0.8 M (NH4)2SO4, 0.1 M Tris HCl pH 7.4–7.7,
and 50–60 mM CdSO4.
X-ray diﬀraction data were collected from single crystals at
100 K at CNR Institute of Biostructure and Bioimages, Naples,
Italy, as previously done for Auoxo3-encapsulated AFt.19
Datasets were processed with HKL2000.37 The results are sum-
marized in Table S1.†
Structure resolution and refinement
Phases have been obtained by molecular replacement using
the program Phaser38 and the coordinates of the protein
extracted from the PDB file 5ERK9 as a starting model. The
refinement of atomic positions and individual B-factor were
carried out using Refmac5.7.39 The inspection of the structure
and analysis of the electron density maps were performed
using Wincoot.40 Gold atoms were identified as previously
described, i.e. considering anomalous, 2Fo-Fc and Fo-Fc elec-
tron density maps. Details of the assignment of Au versus Cd
ions are reported in Table S2.† The structures’ final models are
refined at 1.82 and 2.60 Å resolution to a Rfactor of 0.161 and
0.184 and a Rfree of 0.187 and 0.236, respectively. Refinement
statistics are reported in Table S1.† Coordinates and structure
factors were provided to reviewers and the editor for the review
process and deposited in the Protein Data Bank under the
accession codes 6ENW and 6ENV, respectively. Uninterpreted
peaks of electron density in the Fo-Fc electron density maps
are discussed in Table S3.†
Cell culture and MTT assay
Human breast cancer cells (MCF-7), cervical cancer cells
(HeLa) and rat cardiomyoblast cells (H9c2) were obtained from
ATCC. Human keratinocyte cells (HaCaT) were obtained from
Innoprot. All cell lines were cultured in Dulbecco’s Modified
Eagle’s Medium (Sigma-Aldrich, St Louis, Mo, USA), sup-
plemented with 10% foetal bovine serum (HyClone), 2 mM
L-glutamine and antibiotics, all from Sigma-Aldrich, under a
5% CO2 humidified atmosphere at 37 °C. The growth medium
of H9c2 cells was implemented with 2 mM L-glutamine and
2 mM sodium pyruvate. For dose–response and time-course
experiments, cells were seeded in 96-well plates at a density of
2 × 103 cells per well. 24 h after seeding, increasing concen-
trations of compounds were added to the cells. Cell viability
was assessed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, as described by Monti
et al.41 Cell survival was expressed as the percentage of viable
cells in the presence of the drug compared to controls. Two
groups of cells were used as controls, i.e. cells untreated with
the drug and cells supplemented with identical volumes of
buﬀer. Each sample was tested in three independent analyses,
each carried out in triplicate.
Oxidative stress analyses
To estimate ROS production, the protocol described by Petruk42
was followed, with some modifications. Briefly, MCF-7 cells
were incubated with 7 µg mL−1 of Au2phen-encapsulated AFt
and 12 µg mL−1 of Au2phen alone, for diﬀerent lengths of time
(0–24 h) and then incubated with 2′,7′-dichlorodihydrofluores-
cein diacetate (H2-DCFDA, Sigma-Aldrich). Fluorescence inten-
sity was measured by using a PerkinElmer LS50 spectrofluoro-
meter (525 nm emission wavelength, 488 nm excitation wave-
length, 300 nm min−1 scanning speed and 5 nm slit width for
both excitation and emission). ROS production was expressed
as a percentage of DCF fluorescence intensity of the sample
under test, with respect to the untreated sample. Each value was
assessed by three independent experiments, each with three
determinations. Significance was determined by Student’s t-test.
To analyse the mitochondrial membrane potential (Δψm) the
cells were plated at a density of 2 × 104 cells per well and after
24 h were treated as described above. At the end of treatment,
the cells were incubated with 200 nM cationic lipophilic dye
tetramethylrhodamine ethyl ester (TMRE) for 20 min at 37 °C.
Then, the cells were gently washed with 0.2% BSA in PBS three
times and the fluorescence was measured in a microplate
reader with peak Ex/Em = 549/575 nm. Each value is the mean of
three independent experiments, each with three determi-
nations. Significance was determined by Student’s t-test.
To estimate intracellular glutathione levels, the cells were
plated and treated as described above and then incubated at
37 °C for 6 h. At the end of the incubation, DTNB assay was per-
formed as described by Petruk et al.42 Briefly, the cells were
detached with trypsin and lysed and the protein concentration
was determined by the Bradford assay. Then, 50 µg of proteins
were incubated with 3 mM EDTA and 144 µM 5,5′-dithiobis-2-
nitrobenzoic acid (DTNB) in 30 mM Tris-HCl pH 8.2 and centri-
fuged and the absorbance of the supernatant was measured at
412 nm by using a multiplate reader (Biorad). GSH levels were
expressed as the percentage of TNB absorbance in the sample
under test with respect to the untreated sample. Values are the
mean of three independent experiments, each with triplicate
determination. Significance was determined by Student’s t-test.
For western blotting analyses, the cells were plated at a
density of 2 × 104 cells per cm2 in complete medium for 24 h
and then treated as described above. After 48 h of incubation,
cell lysates were analysed by western blotting performed as
reported by Galano et al.43 Antibodies for phospho-p38, acti-
vated CASP-3 and CASP-8 were purchased from Cell Signal
Technology (Danvers, MA, USA). To normalize protein intensity
levels, a specific antibody against internal standards was used,
i.e. anti-GAPDH (Thermo Fisher, Rockford, IL, USA). The
chemiluminescence detection system (SuperSignal® West
Pico) was from Thermo Fisher.
Conclusions
Ferritin has been used as a scaﬀold for the fabrication of gold
nanoparticles and for the encapsulation of a variety of mole-
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cules, including metallodrugs. Here, taking advantage of the
reversible dissociation of Ft at alkaline pH, we have encapsu-
lated two diﬀerent gold-based anticancer compounds (Au2phen
and Auoxo4), belonging to the Auoxos series, within the ferritin
nanocage and have characterized the adducts formed by X-ray
crystallography. The cytotoxicity of these adducts has been eval-
uated on diﬀerent cell lines. The data have been compared with
those obtained for Auoxo3-encapsulated AFt. As expected,
Auoxo4- and Au2phen-encapsulated AFts exhibit higher cyto-
toxicity than Auoxo3-encapsulated AFt, showing high cyto-
toxicity to MCF-7 and HeLa cell lines in a dose-dependent
manner. The adducts show moderate selectivity, since they kill
tumour cell lines at a lower concentration than that needed to
kill normal cell lines. The structures of the two adducts do not
reveal significant diﬀerences, indicating that the diﬀerences in
the cytotoxicity of the gold-encapsulated AFt depend mainly on
the intrinsic properties of the encapsulated compounds rather
than on the structure of the ferritin adduct obtained upon
encapsulation. In contrast, both the structural and biological
features of the new encapsulated AFts are diﬀerent when com-
pared to those previously reported for Auoxo3-encapsulated AFt.
Diﬀerences are attributed to the diverse propensity of these gold
drugs to undergo hydrolysis and successive reduction.
Surprisingly, the uptake data indicate that the amount of
gold internalized by MCF-7 cells is higher when the cells are
treated with the free drug than in the case of Au2phen-encapsu-
lated AFt. This suggests that internalization of Au2phen-encap-
sulated AFt into cancer cells, which probably occurs via recep-
tor-mediated endocytosis, is less eﬃcient when compared to
the passive diﬀusion of the free drug. However, the drug-loaded
AFt nanocages are more selective than free drugs in killing
cancer cells; the selectivity may reside in the diﬀerent mecha-
nisms of endocytosis of the two molecules. At present, the
origin of the specificity of the ferritin nanocages and of its
higher cytotoxicity when compared to the free drug is still
unknown and will be the subject of further investigations. It is
also unknown if horse spleen apoferritin (composed of 85% L
chains and 15% H chains) enters the cell via TfR1 and/or
Scara5 receptors. Geninatti Crich et al. reported that the chi-
meric nanocage enters the cell via Scara5,44 whereas Zhang and
co-workers reported that the internalization of the H/L-chimeric
Ft nanocage was due to TfR1.36 The higher expression of both
receptors on the cancer cell surface, with respect to normal
cells, could give specificity to the treatment, as supported by the
diﬀerent IC50 values obtained for cancer and normal cells.
Finally, we have demonstrated that Au2phen-encapsulated
AFt is able to alter MCF-7 cell redox homeostasis, thus inducing
apoptosis activation. We hypothesize that the lower sensitivity
of normal cells to Au2phen-encapsulated AFt can be due to the
higher ability of adaptation of normal cells to counteract the
negative eﬀects of oxidative stress and, in turn, to cell death.
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